Pegylated Recombinant Human Granulocyte Colony-stimulating Factor
- Generic Name
- Pegylated Recombinant Human Granulocyte Colony-stimulating Factor
- Indication
⑴非髓性恶性肿瘤患者在接受会发生有临床意义发热性中性粒细胞减少的抑制骨髓的抗肿瘤药治疗时，使用本品可降低发热性中性粒细胞减少引起的感染发生率。
⑵本品不用于造血干细胞移植的外周血祖细胞的动员。
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 586
- Registration Number
- NCT04554056
- Locations
- 🇨🇳
Fudan University Affiliated Cancer Hospital, Shanghai, China
Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04542356
- Locations
- 🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04500886
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, China
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT04497688
- Locations
- 🇨🇳
The fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04239001
- Locations
- 🇨🇳
Chinese PLA General Hospital First medical center, Beijing, China
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
Phase 4
- Conditions
- Lymphoma, Non-HodgkinGranulocyte Colony-Stimulating FactorCost-Benefit Analysis
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT04083079
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Peking University
- Target Recruit Count
- 104
- Registration Number
- NCT04009941
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 485
- Registration Number
- NCT03870412
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Hospital, Guangzhou, China
Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
Phase 4
Terminated
- Conditions
- Ovarian NeoplasmsAdjuvant ChemotherapyOvarian Cancer
- Interventions
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 68
- Registration Number
- NCT03858166
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
- Conditions
- Chemotherapy-induced NeutropeniaMyelosuppression
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 1500
- Registration Number
- NCT03846414
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath